SG190088A1 - Compositions of a peptide targeting system for treating cancer - Google Patents

Compositions of a peptide targeting system for treating cancer Download PDF

Info

Publication number
SG190088A1
SG190088A1 SG2013033451A SG2013033451A SG190088A1 SG 190088 A1 SG190088 A1 SG 190088A1 SG 2013033451 A SG2013033451 A SG 2013033451A SG 2013033451 A SG2013033451 A SG 2013033451A SG 190088 A1 SG190088 A1 SG 190088A1
Authority
SG
Singapore
Prior art keywords
polypeptide
cell
sirna
domain
nanoparticle
Prior art date
Application number
SG2013033451A
Other languages
English (en)
Inventor
Thomas Primiano
Bey-Dih Chang
Jeremy Heidel
Original Assignee
Peptimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptimed Inc filed Critical Peptimed Inc
Publication of SG190088A1 publication Critical patent/SG190088A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG2013033451A 2010-11-01 2011-11-01 Compositions of a peptide targeting system for treating cancer SG190088A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45612710P 2010-11-01 2010-11-01
PCT/US2011/058856 WO2012061443A2 (en) 2010-11-01 2011-11-01 Compositions of a peptide-based system for cell-specific targeting

Publications (1)

Publication Number Publication Date
SG190088A1 true SG190088A1 (en) 2013-06-28

Family

ID=44971106

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013033451A SG190088A1 (en) 2010-11-01 2011-11-01 Compositions of a peptide targeting system for treating cancer
SG10201508981YA SG10201508981YA (en) 2010-11-01 2011-11-01 Compositions Of A Peptide-Based System For Cell-Specific Targeting

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201508981YA SG10201508981YA (en) 2010-11-01 2011-11-01 Compositions Of A Peptide-Based System For Cell-Specific Targeting

Country Status (10)

Country Link
US (2) US8680045B2 (enExample)
EP (1) EP2635308A2 (enExample)
JP (2) JP6189215B2 (enExample)
KR (1) KR20130103562A (enExample)
CN (1) CN103313730B (enExample)
AU (2) AU2011323508B2 (enExample)
BR (1) BR112013010911A2 (enExample)
CA (1) CA2816584A1 (enExample)
SG (2) SG190088A1 (enExample)
WO (1) WO2012061443A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
SG11201701402QA (en) 2014-08-27 2017-03-30 Peptimed Inc Anti-tumor compositions and methods
CA2970478A1 (en) 2014-12-10 2016-06-16 S-Aima Holding Company, Llc Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
CN108463244B (zh) 2015-08-04 2022-05-27 杜克大学 用于递送的基因编码的固有无序隐形聚合物及其使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
CN110023326A (zh) 2016-09-23 2019-07-16 杜克大学 具有lcst行为的非结构化无重复多肽
CN106822036B (zh) * 2016-12-15 2022-08-09 国家纳米科学中心 特异靶向多肽自组装纳米载体、载药纳米颗粒及制备方法
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018175899A1 (en) * 2017-03-24 2018-09-27 The Regents Of The University Of Colorado, A Body Corporate Targeted nanogels for urinary bladder therapies
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
JP7289029B2 (ja) 2017-07-10 2023-06-09 エスアールアイ インターナショナル 分子誘導システムペプチド及びその使用
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019213150A1 (en) 2018-04-30 2019-11-07 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
WO2020081716A2 (en) * 2018-10-16 2020-04-23 Texas Tech University System Biomaterials for 3d cell growth and differentiation
EP3996684A4 (en) * 2019-07-09 2024-06-19 Ariz Precision Medicine, Inc. CANCER TREATMENT USING TARGETED PHARMACEUTICAL SIRNA FORMULATIONS TO DECREASE THE EXPRESSION OF THE PRDM14 PROTEIN
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
JP2023526328A (ja) 2020-05-14 2023-06-21 エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療
CN117138067A (zh) * 2022-05-23 2023-12-01 安徽医科大学 99mTc-DOTA-GVR及其制备方法与应用
EP4644412A1 (en) * 2022-12-27 2025-11-05 NexThera Co., Ltd. Manufacture of elastin-like polypeptide-based recombinant protein and animal cell expression platform thereof
CN120019823A (zh) * 2023-11-20 2025-05-20 湖南中晟全肽生物科技股份有限公司 一种放射性标记的类弹性蛋白多肽及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
AU4412096A (en) 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US20030035829A1 (en) 1997-07-24 2003-02-20 Townsend And Townsend And Crew Liposomal compositions for the delivery of nucleic acid catalysts
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1159441B8 (en) 1999-03-10 2008-10-29 Marie Curie Cancer Care Delivery of nucleic acids and proteins to cells
JP2003511393A (ja) 1999-10-07 2003-03-25 エイブイアイ バイオファーマ， インコーポレイテッド アンチセンス組成物および癌処置法
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
WO2001094393A2 (de) * 2000-06-09 2001-12-13 IPK Institut für Pflanzengenetik und Kulturpflanzenforschung Synthetische spinnenseidenproteine und deren expression in transgenen pflanzen
CN1547617A (zh) * 2001-06-25 2004-11-17 2 肿瘤学药物革新
KR20070085113A (ko) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
WO2007002362A2 (en) * 2005-06-24 2007-01-04 Duke University A direct drug delivery system based on thermally responsive biopolymers
EP1940873A2 (en) * 2005-10-17 2008-07-09 Enkam Pharmaceuticals A/S Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
WO2007134245A2 (en) * 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
US8241623B1 (en) * 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
US9358308B2 (en) 2016-06-07
WO2012061443A2 (en) 2012-05-10
JP2014504150A (ja) 2014-02-20
WO2012061443A3 (en) 2012-08-23
CA2816584A1 (en) 2012-05-10
US20120208742A1 (en) 2012-08-16
JP2016171801A (ja) 2016-09-29
AU2011323508A1 (en) 2013-06-13
EP2635308A2 (en) 2013-09-11
US20140220045A1 (en) 2014-08-07
JP6189215B2 (ja) 2017-08-30
AU2017208213A1 (en) 2017-08-10
KR20130103562A (ko) 2013-09-23
US8680045B2 (en) 2014-03-25
AU2011323508B2 (en) 2017-04-27
SG10201508981YA (en) 2015-11-27
CN103313730A (zh) 2013-09-18
CN103313730B (zh) 2016-06-01
BR112013010911A2 (pt) 2017-05-02

Similar Documents

Publication Publication Date Title
AU2011323508B2 (en) Compositions of a peptide targeting system for treating cancer
Chen et al. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy
KR20080041145A (ko) 암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법
JP2012532613A (ja) Ｓｐａｒｃアンチセンス組成物及びその使用
EP3289084B1 (en) siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
US20160362693A1 (en) Reagents and Methods for Treating Cancer
Vorhies et al. Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
JP4852539B2 (ja) 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
KR20240161932A (ko) Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
WO2025210585A2 (en) Nucleic acid aptamers recognizing the extra cellular domain of alpha7/beta1 integrin dimers and uses thereof
US20060122118A1 (en) Therapeutic compositions and methods of using same